Please ensure Javascript is enabled for purposes of website accessibility

3 High-Growth Stocks Truly Headed for the Moon

By Cory Renauer - Jul 16, 2021 at 6:19AM

Key Points

  • Investing in businesses on the cutting edge of kidney failure prediction, edge computing, and insurance shopping could make you very rich.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out why these niche businesses keep growing by leaps and bounds.

High-growth stocks have been wildly popular lately and it's not hard to see why. A 10-bagger stock pick can allow you to come out ahead even if a dozen other bets blow up in your face.

These three stocks have already produced outstanding gains and there's a good chance they can do it again. Read on to see why investors looking for growth stocks to buy will want to learn more about edge computing, insurance shopping, and kidney failure prediction. 

Three people looking at a laptop computer.

Image source: Getty Images.

Renalytix AI

Renalytix AI (RNLX 6.91%) is using a proprietary algorithm to direct limited resources toward chronic kidney disease (CKD) patients at risk of severe damage. This is a huge underappreciated space that's ripe for disruption. Each year, Medicare spends more than $120 billion managing CKD for more than an estimated 37 million Americans.

The vast majority of CKD-related spending is generated by less than 1 million patients who have progressed to end-stage kidney disease. That's because these patients require regular dialysis treatments or hyper-expensive kidney transplants if they're lucky enough to receive them. Vigilant monitoring of all CKD patients before they progress to end-stage kidney disease would be ideal but impractical. Renalytix AI helps healthcare systems discern which CKD patients need attention now to prevent them from progressing.

Between 8 million and 11 million Americans have CKD due to type 2 diabetes or diabetic kidney disease (DKD). Last August, Renalytix applied for FDA clearance of its KidneyIntelX diagnostic based on successful clinical trial results from a DKD outcome study. Patients labeled low risk by KidneyIntelX were far less likely to experience severe kidney damage down the road than patients deemed low risk by traditional methods.

If approved, we can expect rapid sales growth thanks to the recently finalized Medicare Coverage of Innovative Technology rule. The new rule means new breakthrough devices and diagnostics like KidneyIntelX can receive a national coverage determination (NCD) the moment they're cleared by the FDA. With an NCD, receiving government reimbursement for KidneyIntelX would be a relative breeze.

Fastly

About a month ago, we saw just how important Fastly's (FSLY -2.68%) content delivery network (CDN) has become to the internet at large. Governments, newspaper publishers, and even The Motley Fool served visitors error messages on the morning of June 8, 2021, after one of the company's clients uncovered a software bug.

Fastly figured out the problem and restored 95% of its network within 49 minutes. Since then, the stock's been under pressure as investors anticipate customers switching back to more established competitors like Akamai (AKAM 0.07%).

Fastly's depressed price looks like an opportunity to buy an up-and-coming leader in the CDN space at a discount. Fastly's edge platform allows developers to build highly customized applications they would rather not relocate. Don't be surprised if this edge computing stock bounces back before the end of the year. 

EverQuote

This company is changing how people shop for insurance. EverQuote (EVER 1.32%) allows consumers to shop for insurance products from providers like Travelers and Progressive without having to fill out separate forms. 

Selling consumer referrals to insurance providers is a lucrative business that's growing fast. The company reported total revenue that rose 28% year over year to $104 million during the first quarter. Last year, adjusted earnings before interest, taxes, depreciation, and amortization more than doubled to reach $18.4 million.

EverQuote expects $438 million in total revenue this year, which is just a tiny fraction of the amount insurers spend trying to reach customers. According to EverQuote, the insurance industry will spend around $16.7 billion on advertising in 2024. Insurance providers that aren't digital natives are beating a path to EverQuote's door because it's just about the only place where potential customers can actively shop for policies. 

Americans are spending more time online, and with this secular trend pushing new insurance customers into EverQuote's arms, the company could keep growing by leaps and bounds for years to come.

Cory Renauer owns shares of Renalytix AI plc. The Motley Fool owns shares of and recommends Fastly and Renalytix AI plc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Renalytix AI plc Stock Quote
Renalytix AI plc
RNLX
$2.63 (6.91%) $0.17
Akamai Technologies, Inc. Stock Quote
Akamai Technologies, Inc.
AKAM
$96.28 (0.07%) $0.07
EverQuote, Inc. Stock Quote
EverQuote, Inc.
EVER
$11.48 (1.32%) $0.15
Fastly, Inc. Stock Quote
Fastly, Inc.
FSLY
$11.27 (-2.68%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.